ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RYTM / forecast
LGND (62) BLTE (36) MANE (55) IONS (26) ⌘ Pro Terminal →

Rhythm Pharmaceuticals Inc. (RYTM) 12-Month Stock Forecast & Price Target Cone

$93.44 +0.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $93.42

Rhythm Pharmaceuticals Inc. (RYTM) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $6.37B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RYTM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RYTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $93.44 (+0.94% 1D, market cap $6.37B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, RYTM ranks #495 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RYTM compare to LGND and BLTE in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RYTM carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 89.7%, and ROIC of -29.6%. By comparison, LGND (Ligand Pharmaceuticals Incorporated) holds a C grade (62/100 RQD, P/E 50.8x, ROIC 3.0%, cap $6.43B) and BLTE (Belite Bio Inc) posts a D- grade (36/100 RQD, P/E N/A, ROIC -15.9%, cap $6.23B). Among the 5-stock peer group, LGND leads on earnings multiple (50.8x) while LGND leads on capital efficiency (3.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RYTM?
▼

Per RYTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001649904), Rhythm Pharmaceuticals Inc. generated $189.8M in revenue (+45.8% YoY), -$196.5K in net income, and -$116.6M in free cash flow against $480.2M in total assets and $100.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $93.42 (-0.02%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510038
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (6)Whales (8)SEC (14)Macro (5)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$128 Bull$85 Base$66 Bear
📬 FREE RYTM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RYTM)Realized 20D OHLCV Swing Band: ±6.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY RYTM SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (37% of score)

Altman Z-Score 14.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (21% of score)

20D Institutional Volume Accumulation (±6.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
30
Grade E$86.71+2.2% Next Q
Q2 (-2Q)
33
Grade E$88.62+3.8% Next Q
Q3 (-1Q)
35
Grade E$91.97+1.6% Next Q
Current
38
Grade D-$93.44-7.8% Hist 90D α
Trajectory: E (30) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RYTM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RYTM currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($96.06) and Max Pain ($98.11) forces dealer call-delta covering toward $128.31.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RYTM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RYTM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your RYTM Position Size: $10,000

Shares at $93.44: 107.0 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $66.32
$7,098
$-2,902 (-29.0%)
12M Consensus BaseTarget $85.03
$9,100
$-900 (-9.0%)
12M Bull Case BreakoutTarget $128.31
$13,732
+$3,732 (+37.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$8874%A
Goldman SachsSector Coverage LeadUNDERPERFORM$12169%B
JP MorganUS Large-Cap ResearchSELL$7658%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RYTM)

  • ✓Walkthrough of RYTM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RYTM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.18%📐 HORIZONTAL RANGE
2026-11-03O $93.07H $93.44L $92.57C $93.44VOL 431.7K
RES: $128.6SUP: $81.72SMA50: $96.06SMA200: $96.94
$122.5$111.2$100.0$88.82$77.61RES $128.6SUP $81.72$93.442026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RYTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RYTM Butterfly Map → + Track RYTM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.5%/yr Implied 5Y Growth

vs. +45.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RYTM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RYTM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RYTM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RYTM)

Health Care Rank #495 of 1015 ⚔️ LGND vs RYTM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RYTM vs. LGND, BLTE, MANE, IONS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Rhythm Pharmaceuticals Inc. (RYTM) ranks #495 by composite RQD confidence (38/100, grade D-) and #141 by equity capitalization ($6.37B). Within this direct 5-issuer industry benchmark cohort, LGND leads on earnings valuation at 50.8x trailing P/E, while LGND leads on capital efficiency and profitability with 3.0% ROIC and — gross margin. LGND currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with RYTM at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RYTM ACTIVE
Rhythm Pharmaceuticals Inc.
D- 38/100 — 89.7% -29.6% +0.94% $6.37B Benchmark Subject
LGND
Ligand Pharmaceuticals Incorporated
C 62/100 50.8x — 3.0% -4.87% $6.43B /lgnd-vs-rytm →
BLTE
Belite Bio Inc
D- 36/100 — — -15.9% -0.69% $6.23B /blte-vs-rytm →
MANE
Veradermics Incorporated
D+ 55/100 — — -11.9% -7.27% $5.84B /mane-vs-rytm →
IONS
Ionis Pharmaceuticals Inc.
E 26/100 — 96.0% -20.9% -5.24% $7.23B /ions-vs-rytm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001649904 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rhythm Pharmaceuticals Inc. (RYTM) reported GAAP revenue of $189.8M (+45.8% vs. FY2024 revenue of $130.1M , and +145.1% cumulative change since FY2023) , GAAP net income of -$196.5K, operating cash flow of -$115.7M, and free cash flow of -$116.6M (-2.4% YoY). On the balance sheet, RYTM closed FY2025 with $480.2M in total assets against $100.9M in total debt (Altman Z-Score: 14.33, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $189.8M -$196.5K -$115.7M -$116.6M $480.2M $100.9M
FY2024 (FY) 2024-12-31 $130.1M -$260.6K -$113.9M -$113.9M $392.3M $108.3M
FY2023 (FY) 2023-12-31 $77.4M -$184.7K -$136.2M -$139.6M $3.52B $824.7M

3. RYTM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RYTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $93.44 (+0.94% 1D, market cap $6.37B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, RYTM ranks #495 in composite RQD confidence.

How does RYTM compare to LGND and BLTE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RYTM carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 89.7%, and ROIC of -29.6%. By comparison, LGND (Ligand Pharmaceuticals Incorporated) holds a C grade (62/100 RQD, P/E 50.8x, ROIC 3.0%, cap $6.43B) and BLTE (Belite Bio Inc) posts a D- grade (36/100 RQD, P/E N/A, ROIC -15.9%, cap $6.23B). Among the 5-stock peer group, LGND leads on earnings multiple (50.8x) while LGND leads on capital efficiency (3.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RYTM?

Per RYTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001649904), Rhythm Pharmaceuticals Inc. generated $189.8M in revenue (+45.8% YoY), -$196.5K in net income, and -$116.6M in free cash flow against $480.2M in total assets and $100.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RYTM trading relative to its 50-day, 200-day, and 52-week technical levels?

RYTM last traded at $93.44 (+0.94% on volume of 2,003,985 shares), positioning the stock -2.73% below its 50-day simple moving average ($96.06) and -3.61% below its 200-day simple moving average ($96.94). Across its 52-week range of $74.50 to $122.20, RYTM sits at the 39.7% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($87.37 to $99.51).

Direct Sub-Reports: RYTM RQD Cockpit RYTM 12M Forecast RYTM Earnings & Move RYTM Dividends & DRIP RYTM Insiders & 13F RYTM Whale Options RYTM Profit Sankey RYTM News & Why
ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

RYTM — Rhythm Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Rhythm Pharmaceuticals Inc. (RYTM) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $93.44 (+0.94% 1D, market capitalization $6.37B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -29.6%, gross margin of 89.7%, operating margin of -60.0%, and free cash flow yield of -1.82%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (14/20): Incorporates a 0.96x equity beta, Altman Z-Score of 14.33, Piotroski F-Score of 5/9, and Debt/Equity of 0.73x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Rhythm Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the market data, the company reports a gross margin of 89.7%. Per the news wire, its public narrative centers on Prader-Willi and genetically defined obesity therapies. —: specific products, customer segments, and revenue mix.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Rhythm Pharmaceuticals Inc. (RYTM) reported $189.8M in annual revenue (up from $130.1M in FY2024, +45.8% YoY) and -$196.5K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($77.4M revenue, -$184.7K net income) through FY2025, RYTM scaled operating cash flow to -$115.7M and free cash flow to -$116.6M, backed by $480.2M in total assets against $100.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -1.82% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $74.50 – $122.20 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 0.96x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

—: upstream suppliers, downstream customers, contract manufacturers, and sector correlation data. A prospective investor should note that the absence of mapped dependencies means second-order bottlenecks cannot be assessed from these sources.

  • Key Question #1: Can RYTM sustain or expand its -60.0% operating margin and -29.6% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $189.8M and free cash flow of -$116.6M, how will capital allocation balance growth reinvestment against $100.9M in total debt?
  • Key Question #3: How sensitive is RYTM's 33.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.96x)?

RYTM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rhythm Pharmaceuticals Inc. (RYTM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RYTM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RYTM Bull vs. Bear Conversation Board — What's Your Call at $93.44?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RYTM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RYTM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $122.19 (+32.0%)
📌 Pinned Debate

Revenue grew from $77.4M in FY 2023 to $189.8M in FY 2025 and the Altman Z-Score of 14.33 signals a sturdy balance sheet.

Long RYTM at $92.57 targeting $122.19. Revenue grew from $77.4M in FY 2023 to $189.8M in FY 2025 and the Altman Z-Score of 14.33 signals a sturdy balance sheet.. Institutional whale score is 8/20 and the risk/reward vs. the $74.50 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd 🐂 BULL

@QuantViper Agree on the RQD 38/100 quality, though with 0.96 beta I'm scaling in with half-size at $92.57 and keeping dry powder in case we test $86.09.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $70.35 (-24.0%)
Spot @ $92.57

Operating income of -$192.0M and FCF of -$116.6M in FY 2025 against ROIC of -29.6% show the business is not yet converting growth into

Fading this rally in RYTM at $92.57. Operating income of -$192.0M and FCF of -$116.6M in FY 2025 against ROIC of -29.6% show the business is not yet converting growth into cash.. With a beta of 0.96 and the stock sitting at $92.57 (52-wk range $74.50–$122.20), the easy multiple expansion is already priced in.

LIVE TAPE